Clinical Trial

Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a randomized, open-label, phase IB/II clinical study to evaluate the safety and preliminary efficacy of CM313(SC) injection in patients with Platelet Transfusion Refractoriness.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-01-19; most recent amendment 2025-08-11.
Status change: Not Yet Recruiting → Recruiting 2025-08-11
Trial Details
NCT Number NCT06792019
Lead Sponsor Keymed Biosciences Co.Ltd
Conditions Platelet Transfusion Refractoriness
Enrollment 110 participants
Start Date 2025-03-25
Primary Completion 2027-11-16 (estimated)
Study Completion 2027-11-16 (estimated)
Updated on ClinicalTrials.gov 2025-08-15